|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 28, 2015 ) Hepatocellular carcinoma (HCC) is a common type of primary liver cancer that arises from the hepatocytes in the liver. HCC is classified by various staging systems such as the Barcelona Clinic Liver Cancer (BCLC) stage and Child Pugh stages. The major risk factors for HCC are hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, and alcohol abuse. HCC is more common in men than women, averaging between two to four times as many cases in men as in women. This could be due to men being more likely to be infected with HBV and HCV, to consume more alcohol, to smoke cigarettes, or to have increased iron stores.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=472261
In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of HCC will increase from 103,308 cases in 2014 to 123,658 cases in 2024 at an Annual Growth Rate (AGR) of 1.97%. Japan had the highest number of diagnosed incident cases of HCC among the 7MM throughout the forecast period. In the 7MM in 2014 there were 38,359 diagnosed incident cases of BCLC stage A, 26,558 cases of BCLC stage B, 26,527 cases of BCLC stage C, and 11,865 cases of BCLC stage D. GlobalData epidemiologists estimated that the 7MM in 2014 had 150,488 five-year diagnosed prevalent cases of HCC, 10,835 diagnosed incident cases of HCC with HBV, and 62,140 diagnosed incident cases of HCC with HCV.
The overall increase in the incidence of HCC in the 7MM was mostly driven by population changes, as GlobalData epidemiologists observed very little historical changes in the incidence of HCC. During the forecast period, changes in alcohol use/abuse among men and women may impact the incidence of HCC in the US and UK. Furthermore, the high prevalence of HCV in Italy and Japan will continue to contribute to HCC incidence.
GlobalData’s epidemiological forecast for the diagnosed incident and the five-year diagnosed prevalent cases of HCC in the 7MM is supported by age- and sex-specific data for the incidence. The one- to five-year relative survival data, which were used for the five-year diagnosed prevalent cases forecast, are supported by country-specific, population-based studies that are representative of the national population in the respective markets.
Scope
The Hepatocellular Carcinoma (HCC) EpiCast Report provides an overview of the risk factors and global trends of HCC in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of HCC in these markets. The diagnosed incident cases of HCC are segmented by age (30–39 years, 40–49 years, 50–59 years, 60–69 years, and 70–79 years, =80 years), sex, BCLC stage at diagnosis, and comorbidity with HBV or HCV.
The HCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The HCC EpiCast series will allow you to -
Develop business strategies by understanding the trends shaping and driving the global HCC market.
Quantify patient populations in the global HCC market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HCC therapeutics in each of the markets covered.
Identify the percentage of HCC incident cases by stage at diagnosis and comorbidity with HBV or HCV.
Browse Detail Report With TOC @ http://www.researchmoz.us/epicast-report-hepatocellular-carcinoma-epidemiology-forecast-to-2024-report.html
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 13
3.3.1 Incidence 13
3.3.2 Relative Survival 14
3.3.3 Stage at Diagnosis 16
3.4 Forecast Methodology 17
3.4.1 Sources Used 22
3.4.2 Sources Not Used 25
3.4.3 Forecast Assumptions and Methods 26
3.5 Epidemiological Forecast of HCC (2014-2024) 29
3.5.1 Diagnosed Incident Cases of HCC 29
3.5.2 Age-Specific Diagnosed Incident Cases of HCC 31
3.5.3 Sex-Specific Diagnosed Incident of HCC 33
3.5.4 Age-Standardized Diagnosed Incidence of HCC 35
3.5.5 Diagnosed Incident Cases of HCC by BCLC Stages 36
3.5.6 Diagnosed Incident Cases of HCC with HBV and HCV Comorbidities 38
3.5.7 Five-Year Diagnosed Prevalent Cases of HCC 40
3.6 Discussion 42
3.6.1 Epidemiological Forecast Insight 42
3.6.2 Limitations of the Analysis 43
3.6.3 Strengths of the Analysis 44
4 Appendix 45
4.1 Bibliography 45
4.2 Physicians and Specialists Included in this Study 49
4.3 Primary Research - Prescriber Survey 51
4.4 About the Authors 52
4.4.1 Epidemiologists 52
4.4.2 Reviewers 52
4.4.3 Global Director of Therapy Analysis and Epidemiology 53
4.4.4 Global Head of Healthcare 54
4.5 About GlobalData 55
4.6 About EpiCast 55
4.7 Disclaimer 56
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=472261
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
